Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Ruth Milz, Carmela Benson, Karl Knight, Jose Antunes, Dean Najarian, Paola-Maria Lopez Rengel, Steven Wang, Ute Richarz, Srihari Gopal & John M Kane. (2023) The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia. Neuropsychiatric Disease and Treatment 19, pages 531-545.
Read now
Read now
Juan Antonio García-Carmona & Sofia Pappa. (2023) Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection in the Treatment of Schizophrenia: A Critical Appraisal. Drug, Healthcare and Patient Safety 15, pages 113-123.
Read now
Read now
Antoine C El Khoury, Charmi Patel, Panagiotis Mavros, Ahong Huang, Li Wang & Richa Bashyal. (2021) Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia. Neuropsychiatric Disease and Treatment 17, pages 3159-3170.
Read now
Read now
Marit B. Rise, Liv Os Stølan, Anette Erdner, Berith Hedberg, Katja Stahl, Jesper Riise, Erik Jedenius & Jette Møllerhøj. (2021) Patients’ perspectives on three-monthly administration of antipsychotic treatment with paliperidone palmitate – a qualitative interview study. Nordic Journal of Psychiatry 75:4, pages 257-265.
Read now
Read now
Srihari Gopal, Jagadish Gogate, Katalin Pungor, Edward Kim, Arun Singh & Maju Mathews. (2020) Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study. Neuropsychiatric Disease and Treatment 16, pages 681-690.
Read now
Read now
Anna Wesołowska, Magdalena Jastrzębska-Więsek, Agnieszka Cios & Anna Partyka. (2020) The preclinical discovery and development of paliperidone for the treatment of schizophrenia. Expert Opinion on Drug Discovery 15:3, pages 279-292.
Read now
Read now
Alicia Lopez & Jose Rey. (2019) Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice. Neuropsychiatric Disease and Treatment 15, pages 449-456.
Read now
Read now
Antoine El Khoury, Charmi Patel, Ahong Huang, Li Wang & Richa Bashyal. (2019) Transitioning from oral risperidone or paliperidone to once-monthly paliperidone palmitate: a real-world analysis among Veterans Health Administration patients with schizophrenia who have had at least one prior hospitalization. Current Medical Research and Opinion 35:12, pages 2159-2168.
Read now
Read now
Articles from other publishers (11)
Young-Chul Chung, Yen Kuang Yang, Ahmad Hatim Sulaiman, Paul Bergmans & Wilson Tan. (2022) Asian Subgroup Analysis of the REMISSIO Study: A Long-Term Efficacy and Safety Study of Paliperidone Palmitate 3-month Formulation in Patients with Stable Schizophrenia in a Naturalistic Clinical Setting. Clinical Psychopharmacology and Neuroscience 20:3, pages 427-439.
Crossref
Crossref
Rosaria Di Lorenzo, Anita Iorio, Margherita Pinelli, Federica Maria Magarini, Mattia Marchi, Andrea Sacchetti, Chiara Calogero, Gian Galeazzi, Paola Ferri, Sergio Rovesti & Alessandro Minarini. (2022) Effectiveness and Quality of Life with Paliperidone Palmitate 3-Monthly in Comparison with Other Long-Acting Drugs. Neuropsychiatric Disease and Treatment Volume 18, pages 829-846.
Crossref
Crossref
Massimo Carlo Mauri, Gemma Franco, Alessandro Minutillo, Silvia Paletta, Chiara Di Pace, Alessandra Reggiori, Sara Baldelli & Dario Cattaneo. (2022) The Switch From Paliperidone Long-Acting Injectable 1- to 3-Monthly. Journal of Clinical Psychopharmacology 42:1, pages 23-30.
Crossref
Crossref
Lorenzo Cellini, Domenico De Donatis, Laura Mercolini, Fabio Panariello, Diana De Ronchi, Alessandro Serretti, Andreas Conca, Davide Gaspari, Giancarlo Giupponi, Gerald Zernig & Vincenzo Florio. (2021) Switch to 3-Month Long-Acting Injectable Paliperidone May Decrease Plasma Levels. Journal of Clinical Psychopharmacology 41:6, pages 694-696.
Crossref
Crossref
Adam J. Savitz, Haiyan Xu, Srihari Gopal, Isaac Nuamah, Maju Mathews & Bernardo Soares. (2019) Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies. Brazilian Journal of Psychiatry 41:6, pages 499-510.
Crossref
Crossref
Charmi Patel, Antoine El Khoury, Ahong Huang, Li Wang, Onur Baser & Kruti Joshi. (2019) Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective Analysis. Advances in Therapy 36:10, pages 2941-2953.
Crossref
Crossref
Qian Cai, Charmi Patel, Edward Kim, Nancy Connolly, Ozgur Tunceli & Antoine C. El Khoury. (2019) Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study. Advances in Therapy 36:4, pages 858-869.
Crossref
Crossref
Paola Bozzatello, Silvio Bellino & Paola Rocca. (2019) Predictive Factors of Treatment Resistance in First Episode of Psychosis: A Systematic Review. Frontiers in Psychiatry 10.
Crossref
Crossref
Jonathan K. Lai & Howard C. Margolese. (2019) A qualitative study of patient experience when switching from paliperidone palmitate once monthly (PP1M) to paliperidone palmitate three monthly (PP3M) long-acting injectable antipsychotic. Schizophrenia Research 204, pages 443-444.
Crossref
Crossref
M. Mathews, S. Gopal, A. Singh, J. Gogate, E. Kim & K. Pungor. (2019) Improvement of negative symptoms in schizophrenia with paliperidone palmitate: 1-month versus 3-month long-acting injectables. European Neuropsychopharmacology 29, pages S101-S102.
Crossref
Crossref
Maral DerSarkissian, Patrick Lefebvre, Kruti Joshi, Brianne Brown, Marie-Hélène Lafeuille, Rachel H. Bhak, Michael Hellstern, Priyanka Bobbili, Brian Shiner, Antoine C. El Khoury & Yinong Young-Xu. (2018) Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans. Clinical Therapeutics 40:9, pages 1496-1508.
Crossref
Crossref